Hepatitis Testing Market by Test Type (Blood Test, Imaging Test, and Liver Biopsy) Technology (Enzyme-linked Immunosorbent Assay [ELISA], Rapid Diagnostic Tests, Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, and Others), End User (Hospital & Diagnostic Laboratories, Blood Banks, and Other End Users): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026473 | Pages: 100 | Industry: Medical Device | Date: Sep 2022 | Type: Global

The market crossed US$ 3.92 billion mark in 2022 and is expected to hit US$ 6.56 billion by 2030, recording a CAGR of 6.66% during the forecast period.

Rising prevalence of hepatitis has significantly increased the demand for hepatitis testing 

There has been a significant increase in the prevalence of hepatitis on a global level which has created the demand for hepatitis testing. Additionally, rising awareness and increase in government initiatives such as educational and awareness campaigns have further supported the growth of the hepatitis testing market. Moreover, supportive regulatory policies along with technological advancements in diagnostics and testing are further expected to promote market growth. On the basis of technology, the ELISA segment is expected to account for the major market share owing to its wide acceptance in clinical practices for the diagnosis of hepatitis.

Within the report, the market is segmented into test type, technology, end user, and geography. By test type, the market is further segmented into blood test, imaging tests, and liver biopsy. On the basis of technology, the market is segmented into Enzyme-linked Immunosorbent Assay (ELISA), rapid diagnostic tests, polymerase chain reaction, isothermal nucleic acid amplification technology, and others. Based on end user, the market is divided into hospital & diagnostic laboratories, blood banks, and other end users. Geographically, the market is segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Growth in biotechnology and biopharmaceutical industries has created opportunities for hepatitis testing market

Hepatitis is caused due to liver inflammation which is differentiated into Hepatitis A, Hepatitis B, and Hepatitis C. Hepatitis testing helps in the diagnosis of disease-causing virus genotype which further helps in the formulation of effective treatment for the patient. Hepatitis testing is done by blood test, genetic material protein testing, and others which help in the easy and accurate diagnosis. The blood test segment is expected to account for the major market share during the forecast period as it is the first line detection method.

Rising awareness and surge in product launches are major factors accelerating the market growth.

Rising awareness among the large population about hepatitis has created the demand for hepatitis testing which has significantly boosted the market growth. Additionally, increase in technologically advanced products for the accurate testing of hepatitis is also expected to drive the market growth. For instance, in July 2022, Roche launched a new dual antigen and antibody diagnostic test for hepatitis C, which helps in the early diagnosis of the virus. Furthermore, increase in hospitals and diagnostics labs along with an increase in global population has further contributed the growth of hepatitis testing market during the forecast period.

Recent strategic developments in hepatitis testing market

The hepatitis testing market has undergone several significant developments, and a few of these have been mentioned below:

  • In July 2022, Roche launched a new dual antigen and antibody diagnostic test for hepatitis C, which helps in the early diagnosis of the virus.
  • In May 2022, Abbott launched the HBsAg Next Qualitative Assay for early detection of the Hepatitis B virus (HBV) in India. Early identification of HBV infections not only helps in preventing or delaying the progression of advanced liver diseases but also reduces the risk of transmission.
  • In November 2021, FDA has reclassified certain antibody and nucleic acid tests for hepatitis C, enabling products to come to market via the less-burdensome 510(k) pathway for the first time.
  • In October 2021, Transasia Bio-Medicals has launched India’s first, high sensitivity testing kit for hepatitis C virus. Based on the latest method, the ErbaLisa HCV Gen 4 Ag+Ab kit, is India’s first and only indigenously developed 4th gen ELISA kit and has been evaluated by the National Institute of Biologicals (NIB).

The hepatitis testing market is driven by several players by implementing strategic activities such as new launches, approvals, and partnerships. Abbott Laboratories, F. Hoffmann La Roche Ltd, Bio-Rad Laboratories, Inc., bioMérieux SA and Grifols, S.A. are among the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Healthcare providers
  • Healthcare-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • Testing kits distributors, sales firms and Laboratories
  • Testing Kits Manufacturers
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Test Type:
    • Blood tests
      • Liver function tests
      • Immunoassays
      • Nucleic Acid Tests
    • Imaging Tests
    • Liver Biopsy
  • Technology
    • Enzyme-linked Immunosorbent Assay (ELISA)
    • Rapid Diagnostic Tests (RDT)
    • Polymerase Chain Reaction (PCR)
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Others
  • End User:
    • Hospital & Diagnostic Laboratories
    • Blood Banks
    • Other End Users
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Abbott Laboratories
    • F. Hoffmann La Roche Ltd.
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • bioMérieux SA
    • Epitope Diagnostics
    • Grifols, S.A.
    • Danaher Corporation
    • DiaSorin S.p.A
    • MedMira; Inc.

Companies profiled
- Abbott Laboratories
- F. Hoffmann La Roche Ltd.
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc.
- bioM?rieux SA
- Epitope Diagnostics
- Grifols, S.A.
- Danaher Corporation
- DiaSorin S.p.A
- MedMira; Inc.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000